TSE:4151Pharmaceuticals
Kyowa Kirin (TSE:4151) Margin Improvement To 13.5% Reinforces Profitability Focus Narratives
Kyowa Kirin (TSE:4151) has wrapped up FY 2025 with fourth quarter revenue of ¥147.4b and basic EPS of ¥65.79, while earnings over the trailing twelve months grew 12% and the company’s five year earnings compound sits at about 5% per year. The company has seen revenue move from ¥132.8b in Q4 2024 to ¥147.4b in Q4 2025, with trailing twelve month EPS at ¥128.07 as margins improved to 13.5% from 12.1%. This sets up a results season in which profitability is firmly in focus for investors.
See our...